Recently Featured

Cellular Mechanisms Behind Diabetes-Derived Vascular Disease Unveiled

May 8, 2026
Recent research has illuminated the complex cellular mechanisms linking diabetes to vascular diseases, particularly peripheral artery disease (PAD), which affects millions worldwide. Diabetes, a condition impacting over half a billion people globally, significantly increases the risk of developing PAD, a condition that can lead to severe complications, including limb amputation. Current therapeutic options for PAD…

Andelyn Partners with S. Korea-Based ENCell to Accelerate Global Delivery of Gene Therapies

May 8, 2026
Andelyn Biosciences and ENCell, both CDMOs, signed a collaboration agreement to create a strategic manufacturing bridge between the United States and Asia-Pacific (APAC) regions to accelerate the global delivery of gene therapies. The partnership leverages both companies’ GMP manufacturing facilities, technical expertise, and regional networks to fast-track the development, manufacturing, and global expansion of client…

Medicare Weight Loss Drug Pilot on Hold as Insurers Withdraw Support

May 8, 2026
The US Government has announced it will cover the costs of weight loss drugs under the Medicare GLP-1 Bridge scheme until December 31, 2027, following a lack of participation from insurers. This decision comes as a response to the reluctance of private insurers to contribute to the pilot program, which aimed to evaluate the effectiveness…

Viral Contamination Still a Challenge for CGT Industry

May 7, 2026
Raw material testing remains a cornerstone of quality control strategies in the cell and gene therapy (CGT) sector, as recent analyses reveal persistent deficiencies in virus detection and inactivation methods. Biopharmaceutical raw materials, including culture media ingredients, reagents, and production cell lines, are identified as the primary sources of viral contamination in drug manufacturing. To…

Ongoing Cases